Cubist Systematic Strategies LLC boosted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Rating) by 77.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,842 shares of the biotechnology company’s stock after buying an additional 14,811 shares during the period. Cubist Systematic Strategies LLC owned approximately 0.08% of REGENXBIO worth $894,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of RGNX. BlackRock Inc. boosted its position in shares of REGENXBIO by 0.3% during the 1st quarter. BlackRock Inc. now owns 6,588,815 shares of the biotechnology company’s stock worth $218,683,000 after acquiring an additional 17,377 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of REGENXBIO by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 4,070,462 shares of the biotechnology company’s stock valued at $135,099,000 after purchasing an additional 16,496 shares during the last quarter. State Street Corp raised its holdings in shares of REGENXBIO by 5.6% during the 2nd quarter. State Street Corp now owns 2,801,494 shares of the biotechnology company’s stock worth $69,197,000 after buying an additional 147,728 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of REGENXBIO by 16.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,254,101 shares of the biotechnology company’s stock worth $33,142,000 after buying an additional 176,607 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in REGENXBIO by 9.7% in the second quarter. Point72 Asset Management L.P. now owns 567,500 shares of the biotechnology company’s stock valued at $14,017,000 after buying an additional 50,233 shares in the last quarter. 80.21% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the stock. Chardan Capital reissued a “buy” rating and issued a $61.00 target price on shares of REGENXBIO in a report on Thursday, March 2nd. SVB Leerink lowered their price target on shares of REGENXBIO from $15.00 to $14.00 and set a “market perform” rating for the company in a report on Monday, January 23rd. Finally, Morgan Stanley cut their price objective on REGENXBIO from $50.00 to $46.00 and set an “overweight” rating on the stock in a report on Monday. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $40.86.
REGENXBIO Trading Down 2.0 %
REGENXBIO (NASDAQ:RGNX – Get Rating) last announced its earnings results on Tuesday, February 28th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.48) by $0.10. REGENXBIO had a negative return on equity of 45.51% and a negative net margin of 248.68%. The business had revenue of $31.35 million during the quarter, compared to analyst estimates of $37.45 million. During the same period last year, the company earned $6.67 EPS. REGENXBIO’s revenue for the quarter was down 92.1% compared to the same quarter last year. As a group, equities analysts expect that REGENXBIO Inc. will post -4.45 earnings per share for the current fiscal year.
REGENXBIO Profile
REGENXBIO, Inc is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.
Featured Stories
- Get a free copy of the StockNews.com research report on REGENXBIO (RGNX)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey’s General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.
